Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: ACCEL DIAGNOSTICS, LLC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2018-11-19 to 2021-11-18
Current total value of award: $724601.63
Description: SBIR TOPIC 97 - PHASE II - MINIMALLY INVASIVE TEST FOR CHEMOTHERAPY-INDUCED CARDIOTOXICITY.